Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7 [6]

Blood

Volumn 107, Issue 3, 2006, Pages 1242-1243

  Fröhling, Stefan ^a   Lipka, Daniel B ^b   Kayser, Sabine ^b   Scholl, Claudia ^b   Schlenk, Richard F ^b   Döhner, Hartmut ^b   Gilliland, D Gary ^b   Levine, Ross L ^a   Döhner, Konstanze ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; AUSTRIA; CONTROLLED STUDY; EXON; GENE MUTATION; GERMANY; HETEROZYGOTE; HUMAN; LETTER; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MUTATIONAL ANALYSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NUCLEOTIDE SEQUENCE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 31544474025     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-09-3644     Document Type: Letter

References (9)

1. Goldman JM. A unifying mutation in chronic myeloproliferative disorders. N Engl J Med. 2005;352:1744-1746.
2. Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood. 2005;105:4187-4190.
3. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Prepublished on May 26, 2005, as DOI 10/1182/blood-2005-03-1320. (Now available as Blood. 2005;106:2162-2168).
4. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia-chromosome negative CML and megakaryocytic leukemia. Blood. Prepublished online on July 21, 2005, as DOI 10.1182/blood-2005-05-1800. (Now available as Blood. 2005;106:3370-3373).
5. Levine RL, Loriaux M, Huntly BJ, et al. The JAK2 V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. Prepublished online on August 4, 2005, as DOI 10.1182/blood-2005-05-1898. (Now available as Blood. 2005;106:3377-3379).
6. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106:1207-1209.
7. Martin P, Papayannopoulou T. HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression. Science. 1982;216:1233-1235.
8. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
9. Liu RY, Fan C, Garcia R, Jove R, Zuckerman KS. Constitutive activation of the JAK2/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell lines. Blood. 1999;93:2369-2379.